CN117701456A - Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease - Google Patents

Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease Download PDF

Info

Publication number
CN117701456A
CN117701456A CN202311774803.8A CN202311774803A CN117701456A CN 117701456 A CN117701456 A CN 117701456A CN 202311774803 A CN202311774803 A CN 202311774803A CN 117701456 A CN117701456 A CN 117701456A
Authority
CN
China
Prior art keywords
bifidobacterium lactis
sperm
reduced
reproductive
enteritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202311774803.8A
Other languages
Chinese (zh)
Other versions
CN117701456B (en
Inventor
马新
陈嘉莉
喻扬
郁雪平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thankcome Biotechnology Suzhou Co ltd
Original Assignee
Thankcome Biotechnology Suzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thankcome Biotechnology Suzhou Co ltd filed Critical Thankcome Biotechnology Suzhou Co ltd
Priority to CN202311774803.8A priority Critical patent/CN117701456B/en
Publication of CN117701456A publication Critical patent/CN117701456A/en
Application granted granted Critical
Publication of CN117701456B publication Critical patent/CN117701456B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention discloses bifidobacterium lactis, a preparation thereof and application thereof in the field of biological medicine technology, and relates to the field of biological medicine technology. The Latin theory of the bifidobacterium lactis is as followsBifidobacterium lactis BB-10ABC, accession numberIs CCTCC NO: M2019011. The bifidobacterium lactis can obviously reduce the inflammatory infiltration level of neutrophils and eosinophils, reduce crypt granuloma, improve the damage of the crypt structure of mucous membrane and the thickening of mucous membrane muscular layer, improve the sperm motility, the motility rate and the sperm related movement parameter level, improve the intestinal microenvironment and reduce the sperm injury. The invention provides a reliable theoretical basis for improving the quality reduction of male sperms caused by ulcerative colitis, and has important significance and wide application prospect.

Description

Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease
Technical Field
The invention relates to the technical field of biological medicine, in particular to bifidobacterium lactis, a preparation thereof and application thereof in reproductive injury or diseases.
Background
Inflammatory bowel disease (Inflammatory Bowel Diseases, IBD) is a chronic inflammatory disease of unknown etiology, including Ulcerative Colitis (UC) and Crohn's Disease (CD). Ulcerative colitis mainly involves the rectum and sigmoid colon, is localized to the colonic mucosal and submucosal layers, is continuously distributed, and slowly and repeatedly attacks. Clinically, abdominal pain, diarrhea, purulent bloody stool and the like are mainly manifested. At present, the treatment of ulcerative colitis is still mainly anti-inflammatory and immunoregulation, and the following 6 types of commonly used medicines are available: aminosalicylic acids, glucocorticoids, immunosuppressants, biologicals, probiotics and anti-infective agents. However, the above-mentioned drug treatments have problems of large side effects, high price, etc.
In the prior art, the enteritis can negatively affect male reproductive system, parmar et al research on the effect of ulcerative colitis on testes, and research finds that the ulcerative colitis is related to testis injury, can lead to DNA injury and sperm DNA injury of testes, and the number of epididymal sperms is obviously reduced, (A R Parmar, P Trivedi, G B Jena, dextran sulfate sodium-induced ulcerative colitis leads to testicular toxicity in mice: role of inflammation, oxidative stress and DNA damage, reprod Toxicol, 2014, 49:171-84.).
Bifidobacteria are gram-positive anaerobic bacteria, a spore-free, non-mobile bacillus, usually in the form of a curve, rod, widely found in the digestive tract of humans and animals, but varying with age and growth environment. Bifidobacteria are a member of the family bifidobacteriaceae, belonging to the phylum actinomycota, and were first isolated from breast-fed infant feces by Tissier in 1899 and have been shown to be one of the major bacterial members of the intestinal microbiota of breast-fed infants (Turroni F, duranti S, bottacini F, et al Bifidobacterium bifidum as an example of a specialized human gut commensal [ J ]. Frontiers in microbiology, 2014, 5:437.).
The prior art discloses that bifidobacterium lactis strain BB01 can induce rapid and sustained enhancement of intestinal epithelial tight junction function in a TLR-2 and P38 kinase dependent manner and protect the intestinal epithelial tight junction barrier in a TLR-2 dependent manner, thereby preventing Dextran Sodium Sulfate (DSS) -induced colitis (Al-Sadi R, dharmamarakash V, nighot P, et Al Bifidobacterium bifidum enhances the intestinal epithelial tight junction barrier and protects against intestinal inflammation by targeting the toll-like receptor-2 pathway in an nf- κb-independent manner [ J ]. International Journal of Molecular Sciences, 2021, 22 (15): 8070.). However, further anti-inflammatory mechanisms and mechanisms of intestinal-testosterone intervention for bifidobacterium lactis strain BB01 remain to be discussed.
Disclosure of Invention
The object of the present invention is to provide bifidobacterium lactis, formulations thereof and use thereof in the treatment of reproductive lesions or disorders.
In the present invention, "Bifidobacterium lactis BB01", "Bifidobacterium lactis BB-10ABC", "and"Bifidobacterium lactisBB01”、“Bifidobacterium lactisBB-10ABC "refers to bifidobacterium lactis with the preservation number of CCTCC NO: M2019011.
In order to achieve the above object, the present invention has the following technical scheme:
in one aspect, the present invention provides a bifidobacterium lactis BB01, which has the Latin chemical nameBifidobacterium lactisBB-10ABC with the preservation number of CCTCC NO: M2019011.
The genus bifidobacterium is a member of the family bifidobacteriaceae, belonging to the phylum actinomycota. Bifidobacteria are gram-positive anaerobic bacteria, a spore-free, non-mobile bacillus, usually in the form of a curved, rod, widely found in the digestive tract of humans and animals.
In yet another aspect, the present invention provides a microbial agent comprising bifidobacterium lactis BB01 as described above.
According to some embodiments of the invention, the microbial inoculum may further comprise a preparation of bifidobacterium lactis BB01.
Further, the preparation is one or more of culture, fermentation liquor and fermentation liquor sediment.
Still further, the culture is obtained by inoculating bifidobacterium lactis into a culture medium.
Further, the culture medium is one or more of MRS culture medium, MC culture medium and BCP culture medium.
Specifically, the microbial inoculum is powder or liquid preparation.
In particular, the microbial agents may be in solid, liquid, semi-solid or any physical form available to those skilled in the art through current or future-occurring techniques that comprise the necessary active ingredients to achieve any of the uses, functions or effects of the present invention.
For some embodiments, the microbial agent is in solid form. Specifically, the powder may be a lyophilized powder.
In particular, the method of preparing the lyophilized powder may be a method currently used conventionally in the art, or may be other methods that may occur in the future to obtain a solid form of the microorganism or the microorganism culture, and it should be clarified that the method of preparing the lyophilized powder should not be a condition limiting the scope of the present invention.
In a further aspect, the invention provides an application of the bifidobacterium lactis BB01 or the microbial inoculum in preparing a medicament for treating, preventing or assisting in treating a reproductive system disease.
Specifically, the reproductive system diseases comprise inflammation-induced male reproductive injury, smoking or alcoholism-induced male reproductive injury, drug-induced male reproductive injury, environmental factor-induced male reproductive injury and obesity-induced male reproductive injury.
Specifically, the inflammation includes enteritis, prostatitis, orchitis, epididymitis, seminal vesiculitis and urethritis.
In particular, the environmental factors include excess PM in the environment 2.5 、PM 10 Sulfur dioxide, nitrogen dioxide, polycyclic aromatic hydrocarbon compounds, phthalate compounds, and electromagnetic radiation.
In particular, the reproductive system disease is male reproductive injury induced by enteritis.
More specifically, the male reproductive injury is one or more of oligospermia, sperm motility decrease, testis tissue injury, sperm head side swing amplitude decrease, sperm linearity decrease, whipping frequency decrease, average angular displacement decrease, forward direction decrease, linear movement speed decrease, average path speed decrease and curve speed decrease.
More specifically, the enteritis is ulcerative colitis.
Still further particularly, the symptoms of ulcerative colitis are weight loss, bloody stool, soft stool, and rotten stool.
In still another aspect, the invention provides an application of the bifidobacterium lactis BB01 or the microbial inoculum in preparing a medicament for treating, preventing or assisting in treating enteritis.
Specifically, the bifidobacterium lactis BB01 or the microbial inoculum reduces the granuloma of the crypt by reducing the inflammatory infiltration level of neutrophils and eosinophils, improves the damage of the crypt structure of the mucous membrane and the thickening of the muscular layer of the mucous membrane, improves the sperm motility and the sperm quality, and improves the ulcerative colitis.
In particular, the enteritis includes, but is not limited to, enteritis, colitis and proctitis.
Further specifically, the enteritis includes, but is not limited to, viral enteritis and bacterial enteritis.
Further specifically, the colitis includes, but is not limited to, ulcerative colitis, ischemic colitis, sigmoiditis, pseudomembranous colitis.
Still more particularly, the colitis is ulcerative colitis.
Further specifically, the proctitis include, but are not limited to, acute proctitis, chronic proctitis, tuberculous proctitis, and radiation proctitis.
In particular, the medicine can be prepared into a loaded bifidobacterium lactis BB01 #Bifidobacterium bifidumAny form of formulation of BB 01).
Preferably, the medicament may comprise a pharmaceutically acceptable carrier.
Further, the pharmaceutically acceptable carrier includes, but is not limited to, excipients, buffers, emulsifiers, stabilizers, diluents, binders, preservatives.
Specifically, the excipient is at least one selected from microcrystalline cellulose, lactose, pregelatinized starch, cyclodextrin, carboxymethyl cellulose and mannitol.
Specifically, the buffer is at least one selected from sodium dihydrogen phosphate, sodium bicarbonate, ammonium bicarbonate, sodium acetate, citrate, histidine and succinate.
Specifically, the emulsifier is at least one selected from magnesium stearate, zinc stearate, calcium stearate, glyceryl stearate, sorbitan isostearate, sorbitan oleate, glycerol oleate and polyglycerol-3 polyricinoleate.
Specifically, the stabilizer is at least one selected from acacia, agar, alginic acid, cellulose ether and carboxymethyl chitin.
Specifically, the diluent is at least one selected from erythritol, mannitol, sorbitol, xylitol, lactose, sucrose, corn starch, potato starch, calcium phosphate, calcium citrate and crystalline cellulose.
Specifically, the binder is at least one selected from ethanol, starch slurry, syrup, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, sodium alginate and polyvinylpyrrolidone.
Specifically, the preservative is at least one selected from methyl hydroxybenzoate, propyl hydroxybenzoate, methyl paraben, ethyl paraben, propyl paraben, chlorobutanol, thimerosal, mercuric oxide, phenoxyethanol, chlorhexidine, benzoic acid, sodium benzoate, chlorocresol, benzalkonium bromide, benzalkonium chloride and ethyl hydroxybenzoate.
In yet another aspect, the present invention provides a medicament for the treatment, prevention or adjuvant treatment of a disease of the reproductive system, said medicament comprising bifidobacterium lactis BB01 as described above or a bacterial agent as described above.
Preferably, the viable count of the bifidobacterium lactis in the medicament is (0.1-10) multiplied by 10 8 CFU/ml or (0.1-10). Times.10 8 CFU/g。
Preferably, the medicine contains the bifidobacterium lactis BB01 or the microbial inoculum.
Preferably, the medicament can also comprise a pharmaceutically acceptable carrier.
Specifically, the dosage form of the medicine is any one of tablets, capsules, granules, ointments, suspensions, powders, injections, emulsions, solutions, drop pills and aerosols.
Specifically, the reproductive system diseases comprise inflammation-induced male reproductive injury, smoking or alcoholism-induced male reproductive injury, drug-induced male reproductive injury, environmental factor-induced male reproductive injury and obesity-induced male reproductive injury.
Further, the reproductive system disease is male reproductive injury induced by enteritis.
Specifically, the medicine can improve one or more of oligospermia, sperm motility decrease, testis tissue injury, sperm head side swing amplitude decrease, sperm linearity decrease, whipping frequency decrease, average angular displacement decrease, forward direction decrease, linear motion speed decrease, average path speed decrease and curve speed decrease.
In yet another aspect, the invention provides a medicament for treating, preventing or assisting in treating enteritis, wherein the medicament comprises the bifidobacterium lactis BB01 or the microbial inoculum.
Preferably, the viable count of the bifidobacterium lactis in the medicament is (0.1-10) multiplied by 10 8 CFU/ml or (0.1-10). Times.10 8 CFU/g。
The beneficial effects of the invention are as follows:
the bifidobacterium lactis BB01 provided by the inventionBifidobacteriumbifidumBB 01) can effectively relieve enteritis and male reproductive injury caused by related causes thereof, and relieve enteritis by improving male sperm motility. The interference of the bifidobacterium lactis BB01 obviously reduces the inflammatory infiltration level of neutrophils and eosinophils, reduces crypt granuloma, improves the phenomena of the damage of a mucous membrane crypt structure, the thickening of mucous membrane myometrium and the like, and obviously improves the total number, the activity rate, the vitality and the related exercise parameter level of sperms so as to relieve the reproductive injury induced by enteritis and further protect intestinal barriers. The invention provides a reliable theoretical basis for improving male reproductive injury induced by enteritis, and has important significance.
Preservation description
Preservation number: cctccc No. M2019011;
classification naming:Bifidobacterium lactisBB-10ABC;
preservation time: 2019, 1 month and 4 days;
preservation unit: china center for type culture Collection;
the preservation unit is abbreviated as: cctccc;
preservation address: eight branches of 299 Wuhan university in Wuhan district of Wuhan, hubei province.
Drawings
FIG. 1 is a H & E stained photograph of a section of colon tissue.
Fig. 2 is a colon histopathological score.
FIG. 3 shows the effect of Bifidobacterium lactis BB01 intervention on sperm morphology and density.
Figure 4 is the effect of bifidobacterium lactis BB01 intervention on sperm count.
Fig. 5 is the effect of bifidobacterium lactis BB01 intervention on sperm motility in sperm damage caused by sperm and enteritis.
FIG. 6 is the effect of Bifidobacterium lactis BB01 intervention on sperm motility in sperm damage caused by sperm and enteritis.
Fig. 7 is the effect of bifidobacterium lactis BB01 intervention on sperm head lateral swing amplitude (Amplitude of lateral head displacement, ALH) in sperm injury caused by sperm and enteritis.
Fig. 8 is the effect of bifidobacterium lactis BB01 intervention on Linearity (LIN) of sperm in sperm damage caused by sperm and enteritis.
Fig. 9 is the effect of bifidobacterium lactis BB01 intervention on the whipping frequency of sperm (Beat cross frequency, BCF) in sperm damage due to sperm and enteritis.
Fig. 10 is the effect of bifidobacterium lactis BB01 intervention on the mean angular displacement of sperm (Mean angular displacement, MAD) in sperm injury caused by sperm and enteritis.
Fig. 11 is the effect of bifidobacterium lactis BB01 intervention on sperm pre-sperm tropism (Straightness coefficient, STR) in sperm injury caused by sperm and enteritis.
FIG. 12 is a graph showing the effect of Bifidobacterium lactis BB01 intervention on the linear motility rate (VSL) of sperm in sperm damage caused by sperm and enteritis.
Figure 13 is the effect of bifidobacterium lactis BB01 intervention on the mean path rate of sperm (Average path velocity, VAP) in sperm damage caused by sperm and enteritis.
Figure 14 is the effect of bifidobacterium lactis BB01 intervention on sperm curve rate (Curvilinear velocity, VCL) in sperm injury caused by sperm and enteritis.
In the drawings, different lowercase letters are marked to indicate that the inter-group variability is remarkablep<0.05 The difference between groups indicated by the same lowercase letters is not obvious [ ]p>0.05)。
Detailed Description
In order to make the technical means, the creation features, the achievement of the purpose and the effect of the present invention easy to understand, the present invention will be further elucidated with reference to the specific embodiments, but the following embodiments are only preferred embodiments of the present invention, not all of them. Based on the examples in the embodiments, those skilled in the art can obtain other examples without making any inventive effort, which fall within the scope of the invention. In the following examples, unless otherwise specified, the methods of operation used were conventional, the equipment used was conventional, and the materials used in the examples were the same.
Basic example separation and purification and identification of bifidobacterium lactis BB01
1. Preparation of experiments
1. Experimental materials
1.1 Instrument for measuring and controlling the intensity of light
Biological safety cabinet, gene amplification instrument, electronic pipette.
1.2 Reagent(s)
Bacteria Genomic DNA Kit (century well), 2X SanTaq PCR Mix premix, lysozyme buffer, 4S Green Plus non-toxic nucleic acid dye, proteinase K solution, DNA molecular weight standard Marker (100-2000 bp), RNase-free double distilled water, TAE buffer (all from Shanghai Biotechnology).
1.3 Consumable material
Test tubes, disposable plates, gloves, alcohol lamps, test tube racks, toothpicks, coating sticks, serum pipettes, PCR octal tubes, 1.5ml centrifuge tubes.
2. Culture medium
2.1 Isolation medium
2.1.1 Improved MRS culture medium
Table 1.
Note that: the L-cysteine solution is added after filtration and sterilization.
Wherein: the L-cysteine concentration was: 5mg/mL, 100mL was added to 1L.
2.1.2 LBS agar
Table 2.
Note that: the culture medium had a precipitate after autoclaving, shaking up and pouring into sterile dishes.
2.1.3 TPY agar
Table 3.
2.2 Enrichment medium
2.2.1 Improved MRS broth
Table 4.
2. Sample dilution and culture
1mL of the homogenized sample was immediately inoculated into 9mL of physiological saline and recorded as 10 -1 The method comprises the steps of carrying out a first treatment on the surface of the Continue the dilution down for 6 gradients, recorded as 10 -2 、10 -3 、10 -4 、10 -5 、10 -6 、10 -7 0.1ml of each concentration of the dilution was extracted, and the mixture was spread on a plate of a separation medium and cultured anaerobically at a constant temperature of 37℃for 72 hours.
3. Separation and purification
And (3) selecting different colony forms, dividing and streaking the different colony forms into different separation culture mediums, performing anaerobic culture at a constant temperature of 37 ℃ for 48 hours, performing microscopic examination on the colony forms, selecting characteristic colonies (dumbbell-shaped, Y-shaped and V-shaped) of the milk bifidobacteria, and repeatedly streaking, separating and purifying.
4. 16S identification and preservation
The purified colonies were inoculated in modified MRS broth in a sterile operation, and cultured in an anaerobic incubator at 37℃for 24 hours, with 16S identification in synchronization:
a. primer(s)
Table 5.
b. PCR system
27F primer solution 1.5. Mu.L, 1492R primer solution 1.5. Mu.L, 2 XPCR MasterMix 25. Mu.L, sterile water 20. Mu.L, template 2. Mu.L.
c. PCR reaction conditions
95 ℃ for 5min;30 cycles: 95 ℃ for 30s;55 ℃ for 30s;72 ℃ for 2min;72℃for 10min.
After NCBI comparison, the fermentation broth of bifidobacterium lactis is identified, and 25% glycerol tubes are frozen for preservation.
EXAMPLE 1 Effect of Bifidobacterium lactis BB01 on sperm damage due to sperm and enteritis
1. Experimental reagent: dextran Sodium Sulfate (DSS), purchased from MP biomedical company (MP Biomedicals LLC) in the united states.
2. Experimental animals: c57BL/6JNifdc male mice weighing 20-22g were purchased from Guangdong Venethol laboratory animal technologies Inc. (license number: SCXK (Guangdong) 2022-0063). The environment is that illumination time is 12-h alternately, the temperature is 20-25 ℃, the relative humidity is 50+/-5 percent, and experimental animals in university and south China are fed in an adaptive manner and are fed freely. The experimental operations were all performed according to the requirements related to the "Ministry of ethics of experimental animals of Nanno university".
3. The experimental method comprises the following steps:
(1) Experimental animal grouping and model establishment
The C57BL/6JNifdc male mice are adaptively fed by adopting common feed, and 4 groups of 32 mice are randomly and averagely divided by using a weight stratification method, wherein 8 mice in each group are respectively: control group, DSS group, dss+bl group (BL is low doseBifidobacterium bifidumBB01,5×10 8 CFU/ml), dss+bh group (BH is high doseBifidobacterium bifidumBB01,5×10 9 CFU/ml). A DSS colitis model was established, and animals were given free-drinking DSS solution (concentration 2%) with pure water for 8 days, followed by plain drinking water for 2 days for modeling.
(2) Intervention treatment
All groups of mice began to intervene on the first day of modeling and the intervention was completed: wherein the control group and the DSS group are respectively filled with water with corresponding volumes, and the DSS+BL group and the DSS+BH group are respectively filled with 0.2mL of bifidobacterium lactis BB01 #Bifidobacterium bifidumBB 01) intervention.
(3) Hematoxylin-eosin staining:
a. colon tissue was paraffin-embedded and sectioned at a thickness of 5 μm.
b. The slices were placed in an oven to bake slices 2h at 70 ℃.
c. Dewaxing to water: xylene soak for 10min x 3 times; soaking in absolute ethanol for 5min×2 times; soaking in 90% ethanol for 5min; soaking in 80% ethanol for 5min; soaking in 70% ethanol for 5min; soaking in deionized water for 5 min.
d. Hematoxylin was used to rapidly stain 35 s and rinsed with running water for 5 min.
e. Eosin flash stain 3 s, running water flash rinse.
f. And (3) dehydration and transparency: soaking in 70% ethanol for 2min; soaking in 80% ethanol for 2min; soaking in 90% ethanol for 2min; soaking in absolute ethanol for 3 min; xylene soak was 5min x 2 times.
g. Mixing neutral gum and fresh xylene at a ratio of 4:1, sealing, and naturally air drying.
h. And (5) photographing and analyzing.
(4) Sperm parameter determination
a. The sperm analyzer was started half an hour in advance and the sperm count plate was pre-heated at 37 ℃. Meanwhile, the water bath kettle is started for half an hour in advance to preheat the normal saline at 37 ℃.
b. The right epididymal tail is placed in 1.0 mL preheated physiological saline to be rapidly sheared, released for 5 minutes at 37 ℃, 10.0 mu L of fully mixed sperm suspension is added into a sperm counting plate, and continuous frame dynamic photographing is carried out on sperm by using a Computer-aided semen analysis system (Computer-aided Semen Analysis System, CASA) for measuring sperm motility and related parameters of movement. And then after the sperm is stationary, carrying out single-frame static photographing on the sperm for analysis of sperm quantity and morphology.
And according to the photographed pictures, the dynamic and static analysis of the sperms is carried out by combining a computer-aided semen analysis system.
4. Experimental results
The invention successfully builds a DSS colitis model, and after the DSS solution is given to animals for free drinking modeling, compared with a control group, the mouse faeces have characteristic phenotypes such as soft faeces, rotten faeces, blood faeces and the like. And the interference of the bifidobacterium lactis BB01 can effectively improve the blood and feces phenomenon.
In combination with the results of H & E staining of colon tissue sections, further pathology scoring analysis was performed on colon tissue. Compared with the control group, the colon tissue of the DSS treatment group has characteristic phenotypes such as inflammatory infiltration, crypt abscess, villus shortening and even complete disappearance, crypt structure deformation, mucosa myolayer thickening and the like (figure 1), and the colon histopathological score is remarkably increased (figure 2). While the intervention of the bifidobacterium lactis BB01 with high dosage obviously reduces the inflammatory infiltration level of neutrophils and eosinophils, reduces crypt granuloma, and improves the phenomena of the damage of the crypt structure of the mucous membrane, the thickening of the muscular layer of the mucous membrane and the like (figure 1).
The sperm morphology and function are thoroughly discussed by using a computer-aided semen analysis system. Compared to the control group, DSS treated groups showed significant reproductive lesions: sperm count (fig. 4) and density (fig. 3) were significantly reduced, sperm motility (fig. 5), sperm motility (fig. 6), sperm head lateral swing amplitude (fig. 7), whipping frequency (fig. 9), average angular displacement were all significantly reduced (fig. 10), sperm linearity was not significantly changed (fig. 8), handedness was not significantly changed (fig. 11), linear movement rate (fig. 12), average path rate (fig. 13), and curve rate (fig. 14) were all significantly slowed down. While bifidobacterium lactis BB01 intervention significantly improved sperm motility and sperm-associated kinetic parameter levels (head-to-side amplitude, whipping frequency, mean angular displacement, linear movement rate, mean path rate, and curve rate) in reproductive lesions caused by enteritis, low doses of bifidobacterium lactis BB01 significantly improved sperm number and density. The invention points out the effect of bifidobacterium lactis BB01 in treating and/or preventing male reproductive injury caused by enteritis, and discovers that bifidobacterium lactis BB01 can be used as a protective component for improving the activity of male sperms and improving the male reproductive injury.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, alternatives, and improvements that fall within the spirit and scope of the invention.

Claims (10)

1. Bifidobacterium lactis BB01, latin's nameBifidobacterium lactis BB-10ABC, which is characterized in that the preservation number is CCTCC NO: M2019011.
2. A microbial agent comprising bifidobacterium lactis BB01 of claim 1.
3. Use of bifidobacterium lactis BB01 of claim 1 or the microbial agent of claim 2 for the manufacture of a medicament for the treatment, prophylaxis or co-treatment of a reproductive system disorder.
4. The use according to claim 3, wherein said disorder of the reproductive system comprises inflammation-induced male reproductive lesions, smoking-or alcoholism-induced male reproductive lesions, drug-induced male reproductive lesions, environmental factor-induced male reproductive lesions and obesity-induced male reproductive lesions.
5. The use according to claim 4, wherein the disorder of the reproductive system is enteritis-induced male reproductive lesions.
6. The use of claim 5, wherein the male reproductive injury is one or more of reduced sperm count, reduced sperm motility, damaged testis tissue, reduced sperm head lateral swing amplitude, reduced sperm linearity, reduced whipping frequency, reduced average angular displacement, reduced handedness, reduced linear velocity, reduced average path velocity, reduced curve velocity.
7. Use of bifidobacterium lactis BB01 of claim 1 or the microbial agent of claim 2 for the manufacture of a medicament for the treatment, prophylaxis or co-treatment of enteritis.
8. A medicament for the treatment, prevention or adjuvant therapy of a disease of the reproductive system, characterized in that it comprises bifidobacterium lactis BB01 according to claim 1 or the bacterial agent according to claim 2.
9. The medicine according to claim 8, wherein the viable count of bifidobacterium lactis in the medicine is (0.1-10) ×10 8 CFU/ml or (0.1-10). Times.10 8 CFU/g。
10. A medicament for the treatment, prevention or adjuvant therapy of enteritis, characterized in that it comprises bifidobacterium lactis BB01 according to claim 1 or the bacterial agent according to claim 2.
CN202311774803.8A 2023-12-22 2023-12-22 Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease Active CN117701456B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311774803.8A CN117701456B (en) 2023-12-22 2023-12-22 Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311774803.8A CN117701456B (en) 2023-12-22 2023-12-22 Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease

Publications (2)

Publication Number Publication Date
CN117701456A true CN117701456A (en) 2024-03-15
CN117701456B CN117701456B (en) 2024-10-01

Family

ID=90147778

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311774803.8A Active CN117701456B (en) 2023-12-22 2023-12-22 Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease

Country Status (1)

Country Link
CN (1) CN117701456B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107636146A (en) * 2015-03-02 2018-01-26 同生公司 It is engineered to treat the bacterium of the disease for the gastrointestinal mucosal barrier benefited from the alimentary canal inflammation of reduction and/or tightened up
CN109122668A (en) * 2018-10-25 2019-01-04 镇江市绿色农业科技有限公司 A kind of store method of hilsa herring sperm
US20230069454A1 (en) * 2021-09-01 2023-03-02 Harbin Sunflower Pharmaceutical Co., Ltd. Bifidobacterium lactis strain for preventing or treating colitis and use thereof
CN116144536A (en) * 2022-12-23 2023-05-23 中科宜康(北京)生物科技有限公司 Composite probiotics fermentation composition for improving male sperm motility and application
CN117070409A (en) * 2023-08-11 2023-11-17 苏州普瑞森生物科技有限公司 Bacterium of bifidobacterium animalis subspecies lactis and application thereof in inflammatory bowel disease
CN117535175A (en) * 2023-10-12 2024-02-09 善恩康生物科技(苏州)有限公司 Composite probiotics and application thereof in preparation of products for preventing or assisting in treating colorectal cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107636146A (en) * 2015-03-02 2018-01-26 同生公司 It is engineered to treat the bacterium of the disease for the gastrointestinal mucosal barrier benefited from the alimentary canal inflammation of reduction and/or tightened up
CN109122668A (en) * 2018-10-25 2019-01-04 镇江市绿色农业科技有限公司 A kind of store method of hilsa herring sperm
US20230069454A1 (en) * 2021-09-01 2023-03-02 Harbin Sunflower Pharmaceutical Co., Ltd. Bifidobacterium lactis strain for preventing or treating colitis and use thereof
CN116144536A (en) * 2022-12-23 2023-05-23 中科宜康(北京)生物科技有限公司 Composite probiotics fermentation composition for improving male sperm motility and application
CN117070409A (en) * 2023-08-11 2023-11-17 苏州普瑞森生物科技有限公司 Bacterium of bifidobacterium animalis subspecies lactis and application thereof in inflammatory bowel disease
CN117535175A (en) * 2023-10-12 2024-02-09 善恩康生物科技(苏州)有限公司 Composite probiotics and application thereof in preparation of products for preventing or assisting in treating colorectal cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FENG T等: "Microorganisms in the reproductive system and probiotic\'s regulatory effects on reproductive health", COMPUT STRUCT BIOTECHNOL J, vol. 20, 30 March 2022 (2022-03-30), pages 1541 - 1553 *
孙庆申等: "双歧杆菌及其产品缓解肠炎症状的研究进展", 乳业科学与技术, vol. 43, no. 4, 1 July 2020 (2020-07-01), pages 29 - 33 *

Also Published As

Publication number Publication date
CN117701456B (en) 2024-10-01

Similar Documents

Publication Publication Date Title
WO2022100633A1 (en) Lactobacillus gasseri for prevention and/or treatment of reproductive tract flora disorder-related diseases
Yan et al. Bifidobacterium longum subsp. longum YS108R fermented milk alleviates DSS induced colitis via anti-inflammation, mucosal barrier maintenance and gut microbiota modulation
CN114574390B (en) Bifidobacterium longum subspecies infantis for relieving colonitis and application thereof
CN112760247B (en) Lactobacillus rhamnosus for preventing and/or treating diseases caused by genital tract flora disorder and/or bone loss
CN110643542B (en) Lactobacillus reuteri capable of relieving Th2 reaction of allergic asthma and application thereof
CN109628359B (en) Lactobacillus reuteri capable of relieving allergic asthma and application thereof
WO2017020784A1 (en) Bacteroides fragilis and application thereof
CN112458007A (en) Lactobacillus crispatus for preventing and/or treating diseases related to genital tract flora disorder
CN115851500B (en) Lactobacillus plantarum and application thereof
CN114231470A (en) Lactobacillus acidophilus capable of relieving ulcerative colitis and application thereof
CN113122466B (en) Enterococcus faecalis and application thereof
CN114292781B (en) Bifidobacterium longum SYSU-02 and application thereof
CN114107133A (en) Enterococcus faecium for resisting rectal tumors and application thereof
CN111117925B (en) Anerostipes sp B2131 bacterium and application thereof in inflammatory bowel disease
CN113797232B (en) Composition with insulin resistance relieving function and application thereof
CN116590181B (en) Lactobacillus paracasei for improving inflammatory reaction caused by microplastic pollution and application thereof
CN117701456B (en) Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease
CN117264814A (en) Lactobacillus rhamnosus with effects of preventing and treating digestive tract diseases
WO2017020783A1 (en) Application of bacteroides fragilis in prevention and/or treatment of meningitis
CN116004416B (en) Application of bifidobacterium bifidum from infant intestinal tract
CN113604400B (en) Novel lactobacillus YUYINGW with diabetes preventing or treating effect
CN111304120B (en) Application of Blautia sp B2132 bacterium in prevention and/or treatment of inflammatory bowel disease
CN111004734A (en) Lactobacillus rhamnosus capable of regulating and controlling relative abundance of acinetobacter in intestinal tract
CN115433700B (en) Arthrobacter sakei and application thereof in preparation of medicines for preventing and treating inflammatory bowel diseases
CN118086148B (en) Lactobacillus rhamnosus NKU FL1-8 and application thereof in relieving alcoholic liver injury

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant